Open AccessLGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma
Author(s) -
Daniela Kocher,
Florian Selt,
Gintvile Valinciute,
Julia Zaman,
David Vonhören,
Stefan Pusch,
Romain Guiho,
Juan Pedro Martı́nez-Barberá,
Andreas von Deimling,
Stefan M. Pfister,
David Jones,
Tilman Brummer,
Olaf Witt,
Till Milde,
Romain Sigaud
Publication year - 2022
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noac079.332
Subject(s) - dabrafenib , mapk/erk pathway , chemotherapy , medicine , trametinib , clinical trial , vincristine , glioma , oncology , cell growth , cancer research , phosphorylation , biology , cancer , vemurafenib , biochemistry , metastatic melanoma , cyclophosphamide , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom